The MSF has been named a founding member of the New Approach Methodologies Developer Coalition (NAMs-DC), a new initiative led by the Critical Path Institute that is changing how drugs get developed.

As C-Path notes ‘Bringing new drugs to market is a costly and time-intensive process, and many promising therapies fail in clinical trials because of safety or efficacy issues that do not surface in animal studies.’ c-path NAMs-DC is working to improve this process with human-relevant tools such as organ chips, advanced cell models, and computational approaches that actually replicate how drugs behave in the human body.

Faster, smarter drug testing means more hope for diseases like Myhre syndrome, where we can't afford to wait decades for answers.

"For a condition as complex and rare as Myhre syndrome, where currently no treatments exist, we need to accelerate the path to clinical trials. Being part of this coalition means we have a direct line into the science that could reshape how treatments are discovered, and we're helping to build it." — Armelle Pindon, Chief Scientific Officer, Myhre Syndrome Foundation

It is especially meaningful that a patient organization is included, because the coalition is designed to bring together the people advancing the science with those who have lived experience and will ultimately benefit from it.

We'll be sharing more as our role in this work unfolds. For now, know that MSF is at the table, representing your interests and accelerating pathways to treatments.

Learn more at c-path.org/nams-dc

About Critical Path Institute
Critical Path Institute® (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide.